Finance

Lists
Why is 6MK up 2,63%?
Dive Deeper
6MK:FRA
Merck & Co Inc
€129,54
+2,63%
(+3,32) 1D
9 Okt., 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 6MK...
Open
€126,48
High
€129,54
Low
€125,74
Mkt. cap
359,22 mjd
Avg. vol.
473,00
Volume
216,00
52-wk high
€134,54
52-wk low
€71,00
No. of employees
74 k
Open
€126,48
High
€129,54
Low
€125,74
Mkt. cap
359,22 mjd
Avg. vol.
473,00
Volume
216,00
52-wk high
€134,54
52-wk low
€71,00
No. of employees
74 k
News stories
From web sources and news partners
Profile
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue. The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products. The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000. In 1891, Merck & Co. was established as the American affiliate of the Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck". Wikipedia
About Merck & Co Inc
CEORobert M Davis
Employees74 k
Founded01 Jan. 1891
Headquarters-
SectorPharmaceutical industry
Websitemerck.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
17,28 mjd
16,40 mjd
16,29 mjd
16,61 mjd
Cost of goods sold
3,74 mjd
4,30 mjd
3,88 mjd
4,13 mjd
Cost of revenue
3,74 mjd
4,30 mjd
3,88 mjd
4,13 mjd
Research and development expenses
4,00 mjd
4,00 mjd
3,56 mjd
9,74 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,48 mjd
2,73 mjd
2,57 mjd
2,78 mjd
Operating expense
6,48 mjd
6,73 mjd
6,12 mjd
12,52 mjd
Total operating expenses
10,23 mjd
11,02 mjd
10,00 mjd
16,65 mjd
Operating income
7,05 mjd
5,38 mjd
6,29 mjd
-40,00 m
Other non operating income
-
41,00 m
42,00 m
59,00 m
EBT including unusual items
6,74 mjd
3,42 mjd
-3,53 mjd
-683,00 m
EBT excluding unusual items
6,76 mjd
4,98 mjd
5,85 mjd
-508,00 m
Income tax expense
958,00 m
458,00 m
709,00 m
654,00 m
Effective tax rate
14,20%
13,39%
-20,06%
-95,75%
Other operating expenses
-
-
-
-
Net income
5,78 mjd
2,96 mjd
-4,24 mjd
-1,34 mjd
Net profit margin
33,49%
18,07%
-26,03%
-8,04%
Earnings per share
2,58
2,04
-1,28
-0,13
Interest and investment income
96,00 m
69,00 m
35,00 m
35,00 m
Interest expense
-327,00 m
-411,00 m
-479,00 m
-525,00 m
Net interest expenses
-231,00 m
-342,00 m
-444,00 m
-490,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
8,15 mjd
6,79 mjd
7,69 mjd
1,43 mjd
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google-programme